COVID and Cardiovascular Disease: What We Know in 2021.

Authors:
Chilazi M; Duffy EY; Thakkar A; Michos ED.

Journal:
Curr Atheroscler Rep

Publication Year: 2021

DOI:
10.1007/s11883-021-00935-2

PMCID:
PMC8117457

PMID:
33983522

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Curr Atheroscler Rep

Abbreviation: Curr Atheroscler Rep

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
How Will Our Practice Change After the CLEAR Outcomes Trial?
Abrahams T; Nelson AJ; Nicholls SJ. (2024) - Transparency Score: 3/6
Lipoprotein(a): from Causality to Treatment.
Kronenberg F. (2024) - Transparency Score: 3/6
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Surma S; Sahebkar A; Banach M. (2024) - Transparency Score: 2/6
Apheresis: What Should a Clinician Know?
Parhofer KG. (2023) - Transparency Score: 3/6
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Giammanco A; Spina R; Cefalù AB and 1 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of InterestThe authors declare no competing interests. Human and Animal Rights and Informed ConsentThis article does not contain any studies with human or animal subjects performed by any of the authors. Conflict of Interest The authors declare no competing interests."

Evidence found in paper:

"Funding Dr Michos is supported by the Amato Fund for Women’s Cardiovascular Health Research at Johns Hopkins University."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025